Richter Transformation clinical trials at UCSF
1 research study open to eligible people
Richter transformation happens when a slow-growing blood cancer turns into a fast-growing one. UCSF is conducting research to see if a new drug, NX-1607, is safe and works against advanced cancers. This study is the first to try NX-1607 in people.
Showing trials for
NX-1607 in Adults With Advanced Malignancies
open to eligible people ages 18 years and up
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
San Francisco, California and other locations
Last updated: